Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8<sup>+</sup> T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment
Through multiple mechanisms of action, ABL112 exerted potent tumor-killing activity and immune memory response alone or in combination with anti-PD-(L)1 therapies, representing a promising new cancer treatment strategy.
Authors
- Wonjun Son
- Kyeongsu Park (ORCID: https://orcid.org/0000-0001-9204-4112)
- Byungje Sung
- Hyunseong Youn
- An Na Seo (ORCID: https://orcid.org/0000-0001-6412-3067)
- Sang Hoon Lee (ORCID: https://orcid.org/0000-0002-7706-5318)
- Sora Kim
- Yangsoon Lee (ORCID: https://orcid.org/0000-0003-1556-686X)
- Jonghwa Won (ORCID: https://orcid.org/0000-0003-2853-8948)
- Yelim Park
Institutions
- ABL Bio (South Korea) (KR)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010728
- Citations
- 3
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 4.08